Crystal Adam 4
4 · Tango Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Tango Therapeutics (TNGX) President Crystal Adam Receives Award & Sells Shares
What Happened
Crystal Adam, President, R&D of Tango Therapeutics (TNGX), received equity awards and had an automatic sell-to-cover transaction. On Feb 2, 2026 she was granted RSU-based awards totaling 332,220 units (47,460 + 284,760 RSUs). On Feb 3, 2026 she sold 18,251 shares at a weighted average price of $12.26 (proceeds $223,708) and 201 shares at a weighted average price of $12.90 (proceeds $2,592), for total proceeds of about $226,300. The awards are reported at $0 acquisition price because they are RSUs/derivative awards.
Key Details
- Transaction dates: Grants dated Feb 2, 2026; sales on Feb 3, 2026. Form filed Feb 4, 2026 (timely).
- Grants: 47,460 RSUs + 284,760 derivative RSUs = 332,220 RSU-related units granted (no cash paid).
- Sales: 18,251 shares @ weighted avg $12.26 (range $11.88–$12.875) and 201 shares @ weighted avg $12.90 (range $12.88–$12.91); total proceeds ≈ $226,300.
- Shares owned after the transactions: not specified in the provided filing.
- Footnotes: F1 describes that the RSUs vest over three years (33% on Feb 1, 2027; 33% on Feb 14, 2028; 34% on Feb 12, 2029, subject to continued service). F2 states the sales were automatic "sell-to-cover" to satisfy tax withholding (not discretionary). F3/F4 give price ranges and note more detailed breakdowns are available on request. F5 describes an option vesting schedule but no option exercise or option sale is reported in this filing.
Context
The sales here were reported as automatic sell-to-cover transactions to satisfy tax withholding obligations associated with RSU vesting (per the filing), which is a routine administrative action rather than an express directional bet on the stock. The RSU grants are derivative awards that will convert to shares only as they vest per the schedule above.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-02+47,460→ 205,670 total - Sale
Common Stock
[F2][F3]2026-02-03$12.26/sh−18,251$223,708→ 187,419 total - Sale
Common Stock
[F2][F4]2026-02-03$12.90/sh−201$2,592→ 187,218 total - Award
Stock Option (Right to Buy)
[F5]2026-02-02+284,760→ 284,760 totalExercise: $11.94Exp: 2036-02-02→ Common Stock (284,760 underlying)
Footnotes (5)
- [F1]These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
- [F2]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F3]Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F4]Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F5]This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.